NeoGenomics (NEO) Stock Forecast & Price Target

Compare

1,907 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NEO Analyst Ratings

Moderate Buy

5 Buy

6 Hold

0 Sell

Based on 11 analysts giving stock ratings to

NeoGenomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NEO Stock 12 Month Forecast

Average Price Target

$13.14

▲(26.35% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $13.14 with a high forecast of $17.00 and a low forecast of $11.00. The average price target represents a 26.35% change from the last price of $10.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","19":"$19","7.75":"$7.75","11.5":"$11.5","15.25":"$15.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.75,11.5,15.25,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.72,9.356923076923078,9.993846153846155,10.630769230769232,11.267692307692307,11.904615384615386,12.541538461538462,13.178461538461539,13.815384615384616,14.452307692307693,15.08923076923077,15.726153846153846,16.363076923076925,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.72,9.06,9.4,9.74,10.08,10.42,10.760000000000002,11.100000000000001,11.440000000000001,11.780000000000001,12.120000000000001,12.46,12.8,{"y":13.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.72,8.895384615384616,9.070769230769232,9.246153846153847,9.421538461538463,9.596923076923078,9.772307692307692,9.947692307692307,10.123076923076923,10.298461538461538,10.473846153846154,10.649230769230769,10.824615384615385,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$13.14

Lowest Price Target$11.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mark Massaro

BTIG

―

Hold

―

Reiterated

10/30/25

BTIG Remains a Hold on NeoGenomics (NEO)We reiterate our Neutral on NEO.

William Bonello

Craig-Hallum

$17

Buy

63.46%

Upside

Reiterated

10/29/25

Craig-Hallum Remains a Buy on NeoGenomics (NEO)

Daniel Brennan

TD Cowen

$12→$14

Buy

34.62%

Upside

Reiterated

10/29/25

Strong Growth Prospects for NeoGenomics: Buy Rating with Increased Price TargetWe view the 2% top-line, ~70bps EBITDA beat vs. Consensus and a continuation of ~11% revenue growth on a CAGR basis as a solid platform through which to build on with MRD and PanTracer liquid launches on track for 1Q:26. Continued net share gain on the ex-NGS clinical business in Q3 would offer further upside potential. We raise our PT to $14 on expected growth acceleration accompanying launches.

Andrew Brackmann

William Blair

―

Hold

―

Assigned

10/29/25

William Blair Sticks to Their Hold Rating for NeoGenomics (NEO)Despite the positive update this morning, we remain at MarketPerform.

Cira Diagnissa

TR | OpenAI - 4o

$10.5→$10

Hold

-3.85%

Downside

Reiterated

10/29/25

AI Generated ArticleAI Generated Article

Bruce Jackson

Benchmark Co.

―

Hold

―

Reiterated

10/29/25

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Its Hold Rating for NeoGenomics (NEO)

Michael Ryskin

Bank of America Securities

$6.5→$11

Hold

5.77%

Upside

Reiterated

10/28/25

NeoGenomics price target raised to $11 from $6.50 at BofANeoGenomics price target raised to $11 from $6.50 at BofA

Puneet Souda

Leerink Partners

$12→$14

Hold

34.62%

Upside

Reiterated

10/28/25

Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism

Michael Matson

Needham

$14

Buy

34.62%

Upside

Reiterated

10/28/25

NeoGenomics' Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

David Westenberg

Piper Sandler

$11

Buy

5.77%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for NeoGenomics (NEO)

Mason Carrico

Stephens

$6.5→$11

Buy

5.77%

Upside

Reiterated

09/02/25

Stephens Keeps Their Buy Rating on NeoGenomics (NEO)Stephens analyst Mason Carrico raised the price target on Neogenomics (NASDAQ: NEO) to $11.00 (from $6.50) while maintaining a Overweight rating.

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

-23.08%

Downside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Matthew Sykes

Goldman Sachs

$17→$15

Buy

44.23%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Tycho Peterson

Jefferies

$22→$18

Buy

73.08%

Upside

Reiterated

02/18/25

Neogenomics (NEO) PT Lowered to $18 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mark Massaro

BTIG

―

Hold

―

Reiterated

10/30/25

BTIG Remains a Hold on NeoGenomics (NEO)We reiterate our Neutral on NEO.

William Bonello

Craig-Hallum

$17

Buy

63.46%

Upside

Reiterated

10/29/25

Craig-Hallum Remains a Buy on NeoGenomics (NEO)

Daniel Brennan

TD Cowen

$12→$14

Buy

34.62%

Upside

Reiterated

10/29/25

Andrew Brackmann

William Blair

―

Hold

―

Assigned

10/29/25

William Blair Sticks to Their Hold Rating for NeoGenomics (NEO)Despite the positive update this morning, we remain at MarketPerform.

Cira Diagnissa

TR | OpenAI - 4o

$10.5→$10

Hold

-3.85%

Downside

Reiterated

10/29/25

AI Generated ArticleAI Generated Article

Bruce Jackson

Benchmark Co.

―

Hold

―

Reiterated

10/29/25

Benchmark Co. Reaffirms Their Hold Rating on NeoGenomics (NEO)

Subbu Nambi

Guggenheim

―

Hold

―

Reiterated

10/28/25

Guggenheim Sticks to Its Hold Rating for NeoGenomics (NEO)

Michael Ryskin

Bank of America Securities

$6.5→$11

Hold

5.77%

Upside

Reiterated

10/28/25

NeoGenomics price target raised to $11 from $6.50 at BofANeoGenomics price target raised to $11 from $6.50 at BofA

Puneet Souda

Leerink Partners

$12→$14

Hold

34.62%

Upside

Reiterated

10/28/25

Balanced Outlook on NeoGenomics: Hold Rating Amid Growth Potential and Long-Term Skepticism

Michael Matson

Needham

$14

Buy

34.62%

Upside

Reiterated

10/28/25

NeoGenomics' Strong Q3 Performance and Strategic Growth Initiatives Reinforce Buy Rating

David Westenberg

Piper Sandler

$11

Buy

5.77%

Upside

Reiterated

10/03/25

Piper Sandler Sticks to Their Buy Rating for NeoGenomics (NEO)

Mason Carrico

Stephens

$6.5→$11

Buy

5.77%

Upside

Reiterated

09/02/25

Stephens Keeps Their Buy Rating on NeoGenomics (NEO)Stephens analyst Mason Carrico raised the price target on Neogenomics (NASDAQ: NEO) to $11.00 (from $6.50) while maintaining a Overweight rating.

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

$10→$8

Hold

-23.08%

Downside

Reiterated

07/30/25

NeoGenomics price target lowered to $8 from $10 at Morgan StanleyNeoGenomics price target lowered to $8 from $10 at Morgan Stanley

Matthew Sykes

Goldman Sachs

$17→$15

Buy

44.23%

Upside

Reiterated

04/16/25

Neogenomics (NEO) PT Lowered to $15 at Goldman SachsGoldman Sachs analyst Matthew Sykes lowered the price target on Neogenomics (NASDAQ: NEO) to $15.00 (from $17.00) while maintaining a Buy rating.

Tycho Peterson

Jefferies

$22→$18

Buy

73.08%

Upside

Reiterated

02/18/25

Neogenomics (NEO) PT Lowered to $18 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeoGenomics

1 Month

xxx

Success Rate

8/17 ratings generated profit

Average Return

+3.22%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of +3.22% per trade.

3 Months

xxx

Success Rate

8/18 ratings generated profit

Average Return

-1.70%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -1.70% per trade.

1 Year

David WestenbergPiper Sandler

Success Rate

9/18 ratings generated profit

Average Return

+7.13%

reiterated a buy rating last month

Copying David Westenberg's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.13% per trade.

2 Years

xxx

Success Rate

6/18 ratings generated profit

Average Return

-9.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -9.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NEO Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NEO has received 12 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. NEO average Analyst price target in the past 3 months is 13.14.

Each month's total comprises the sum of three months' worth of ratings.

NEO Financial Forecast

NEO Earnings Forecast

Next quarter’s earnings estimate for NEO is $0.04 with a range of $0.00 to $0.06. The previous quarter’s EPS was $0.03. NEO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NEO has Preformed in-line its overall industry.

NEO Sales Forecast

Next quarter’s sales forecast for NEO is $188.35M with a range of $186.60M to $193.00M. The previous quarter’s sales results were $187.80M. NEO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NEO has Preformed in-line its overall industry.

NEO Stock Forecast FAQ

What is NEO’s average 12-month price target, according to analysts?

Based on analyst ratings, NeoGenomics’s 12-month average price target is 13.14.

What is NEO’s upside potential, based on the analysts’ average price target?

NeoGenomics has 26.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NEO a Buy, Sell or Hold?

NeoGenomics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 6 hold ratings and 0 sell ratings.

What is NeoGenomics’s price target?

The average price target for NeoGenomics is 13.14. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $11.00. The average price target represents 26.35% Increase from the current price of $10.4.

What do analysts say about NeoGenomics?

NeoGenomics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of NEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

NeoGenomics (NEO) Stock Forecast & Price Target

NEO Analyst Ratings

NEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeoGenomics

NEO Analyst Recommendation Trends

NEO Financial Forecast

NEO Earnings Forecast

NEO Sales Forecast

NEO Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts